JP2007532624A - アルツハイマー病の治療のための療法組合せ - Google Patents

アルツハイマー病の治療のための療法組合せ Download PDF

Info

Publication number
JP2007532624A
JP2007532624A JP2007507862A JP2007507862A JP2007532624A JP 2007532624 A JP2007532624 A JP 2007532624A JP 2007507862 A JP2007507862 A JP 2007507862A JP 2007507862 A JP2007507862 A JP 2007507862A JP 2007532624 A JP2007532624 A JP 2007532624A
Authority
JP
Japan
Prior art keywords
disease
alzheimer
active
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007507862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532624A5 (https=
Inventor
エイチ． ラーソン，グレッグ
Original Assignee
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー filed Critical ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー
Publication of JP2007532624A publication Critical patent/JP2007532624A/ja
Publication of JP2007532624A5 publication Critical patent/JP2007532624A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2007507862A 2004-04-14 2005-04-04 アルツハイマー病の治療のための療法組合せ Withdrawn JP2007532624A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (2)

Publication Number Publication Date
JP2007532624A true JP2007532624A (ja) 2007-11-15
JP2007532624A5 JP2007532624A5 (https=) 2008-05-15

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007507862A Withdrawn JP2007532624A (ja) 2004-04-14 2005-04-04 アルツハイマー病の治療のための療法組合せ

Country Status (14)

Country Link
EP (1) EP1737539A1 (https=)
JP (1) JP2007532624A (https=)
KR (1) KR20060133008A (https=)
CN (1) CN1960781A (https=)
AU (1) AU2005232447A1 (https=)
BR (1) BRPI0509881A (https=)
CA (1) CA2562069A1 (https=)
IL (1) IL178120A0 (https=)
MX (1) MXPA06011969A (https=)
NO (1) NO20065196L (https=)
RU (1) RU2006136361A (https=)
TW (1) TW200533341A (https=)
WO (1) WO2005099823A1 (https=)
ZA (1) ZA200608239B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504872A (ja) * 2016-02-11 2019-02-21 シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ 神経変性疾患の治療に使用するためのイグメシン

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
EP3982956B1 (en) * 2019-06-14 2024-06-12 Joshua O. Atiba Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL164317A0 (en) * 2002-04-02 2005-12-18 Janssen Pharmaceutica Nv Statin therapy for enhancing cognitive maintenance
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2516990A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. Treatment of alzheimer's disease
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504872A (ja) * 2016-02-11 2019-02-21 シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ 神経変性疾患の治療に使用するためのイグメシン
JP7059192B2 (ja) 2016-02-11 2022-04-25 シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ 神経変性疾患の治療に使用するためのイグメシン

Also Published As

Publication number Publication date
IL178120A0 (en) 2006-12-31
EP1737539A1 (en) 2007-01-03
BRPI0509881A (pt) 2007-10-16
ZA200608239B (en) 2008-06-25
NO20065196L (no) 2007-01-03
CN1960781A (zh) 2007-05-09
AU2005232447A1 (en) 2005-10-27
TW200533341A (en) 2005-10-16
KR20060133008A (ko) 2006-12-22
CA2562069A1 (en) 2005-10-27
RU2006136361A (ru) 2008-04-20
MXPA06011969A (es) 2006-12-15
WO2005099823A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
Farooq et al. Pharmacotherapy for vascular cognitive impairment
Rogers et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study
Auriacombe et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
Chase et al. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease
RU2371173C2 (ru) Мемантин для лечения болезни альцгеймера легкой и от легкой до умеренной степени тяжести
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
Jelic et al. Treatment of mild cognitive impairment: rationale, present and future strategies
Banks et al. Memories are made of this: recent advances in understanding cognitive impairments and dementia
Kirshner Mild cognitive impairment: to treat or not to treat
EP2968220B1 (en) Methods and compositions for improving cognitive function
US20230146896A1 (en) Composition and method for treating alzheimer's disease
US20250170203A1 (en) Methods of Treating Alzheimer's Disease
JP2024543053A (ja) 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
CN104582793A (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
Moretti et al. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia
Herrmann Cognitive pharmacotherapy of Alzheimer's disease and other dementias
JP2024525875A (ja) パーキンソン病及び／またはレビー小体型疾患または障害の処置方法
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
CA2205940A1 (en) Medicament comprising a carnitine derivative for treating alzheimer's disease in early-onset patients
JP2007532624A (ja) アルツハイマー病の治療のための療法組合せ
Jann et al. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: A randomized, double-masked, placebo-controlled trial
Fernandez et al. The use of methylphenidate in HIV patients: A clinical perspective
Vande Griend et al. Probable levetiracetam-associated depression in the elderly: two case reports
AU2016235743A1 (en) Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases
Evdokimova et al. The role of cardiovascular diseases in the development of Alzheimer’s disease and cognitive impairment, including COVID-19

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070919

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080328

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080708